Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716675 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 2,699
- Enrollment target
NCT02716675 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 2,699 participants.
The verdict
NCT02716675, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2,699 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America, South America, and Switzerland.
Interventions
- BIOLOGICAL VRC01
- BIOLOGICAL Placebo for VRC01
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,699 participants |
| Start Date | 2016-04-06 |
| Est. Completion | 2020-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716675
The ClinicalTrials.gov registry entry for NCT02716675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 2,699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VRC01 is the first listed.
NCT02716675 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02716675 about?
NCT02716675 is a clinical study titled "Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men". This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America, South America, and Switzerland.
What is the current status of trial NCT02716675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,699 participants. The study started on 2016-04-06. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT02716675?
The interventions under investigation include: VRC01 (BIOLOGICAL), Placebo for VRC01 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02716675?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.